Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech
Aslan $ASLN has stumbled back into the failure pit.
When their lead drug failed to treat gastric cancer, Aslan Pharmaceuticals announced they were going …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
